Development of effective cancer vaccine using targeting system of antigen protein to APCs

Pharmaceutical Research

Volumn 29, Issue 2, 2012, Pages 483-489

  Kurosaki, Tomoaki ^a,b   Kitahara, Takashi ^c   Nakamura, Tadahiro ^c   Nishida, Koyo ^d   Fumoto, Shintaro ^d   Kodama, Yukinobu ^c   Nakagawa, Hiroo ^c   Higuchi, Norihide ^c   Sasaki, Hitoshi ^c,d  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

polyglutamic acid; Benzalkonium chloride; Cancer; Delivery system; Vaccine

Indexed keywords

BENZALKONIUM CHLORIDE; CANCER VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; OVALBUMIN; POLYGLUTAMIC ACID; BENZALKONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; MALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR CELL; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; CHEMISTRY; DENDRITIC CELL; IMMUNOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; BENZALKONIUM COMPOUNDS; CANCER VACCINES; CELL LINE; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; OVALBUMIN; POLYGLUTAMIC ACID;

EID: 84860849727     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0571-x     Document Type: Article

References (21)

1. Tan A, De La Peña H, Seifalian AM. The application of exosomes as a nanoscale cancer vaccine. Int J Nanomed. 2010;5:889-900.
2. Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol. 2010;2010(237623):1-10.
3. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
4. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Canc Immunol Immunother. 2009;58(10):1609-26.
5. Zimmermann VS, Casati A, Schiering C, Caserta S, Hess Michelini R, Basso V, et al. Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination. J Immunol. 2007;179(5):2899-909.
6. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27(5):687-90.
7. Dubensky Jr TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22(3):155-61.
8. Asif M, Jenkins KA, Hilton LS, Kimpton WG, Bean AG, Lowenthal JW. Cytokines as adjuvants for avian vaccines. Immunol Cell Biol. 2004;82(6):638-43.
9. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008;65(20):3231-40.
10. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006;12(5):216-22.
11. Kurosaki T, Kitahara T, Fumoto S, Nishida K, Nakamura J, Niidome T, et al. Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials. 2009;30(14):2846-53.
12. Kurosaki T, Kitahara T, Kawakami S, Nishida K, Nakamura J, TeshimaM, et al. The development of a gene vector electrostatically assembled with a polysaccharide capsule. Biomaterials. 2009;30(26):4427-34.
13. Shuaibu MN, Cherif MS, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, et al. Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 Cterminal. Vaccine. 2011;29(17):3239-47.
14. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Kayamuro H, et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine. 2008;26(10):1303-13.
15. Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy. 2010;2(1):57-68.
16. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64-73.
17. Neyestani TR, Woodward WD, Hillyer L. Serum levels of Th2-Type immunoglobulins are increased in weanling mice subjected to acute wasting protein-energy malnutrition. Iran J Allergy Asthma Immunol. 2004;3(1):1-6.
18. Prodhomme EJ, Tutt AL, Glennie MJ, Bugg TD. Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab′) and glycopeptide ligands. Bioconjug Chem. 2003;14(6):1148-55.
19. Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, et al. Poly(gamma, L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials. 2006;27(35):5958-65.
20. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130(1):131-41.
21. Liebert MA. Final report on the safety assessment of benzalkonium chloride. Int J Toxicol. 1989;8(4):589-625.